Genotype

Genotype is the particular combination of gene variants an individual inherits — the underlying DNA sequence, as distinct from the observable traits that sequence and environment together produce. Two people with similar bodies and habits can carry meaningfully different genotypes, and those differences can have real pharmacological consequences.

On Psychedex, the term appears almost exclusively in a pharmacogenomic context: variants in genes that encode drug-metabolizing enzymes or transporter proteins. These inherited differences determine how quickly a given substance is broken down, how much of it reaches its site of action, and which metabolites accumulate in the body. Because genotype is fixed at conception, it does not change with use or lifestyle.

How it works · its role

The cytochrome P450 enzyme family — particularly CYP2D6, CYP2C19, and CYP3A4 — processes a large share of commonly used psychoactive substances, and each of these enzymes is encoded by a gene carrying many known variants. An individual may inherit copies that make the enzyme function normally, partially, not at all, or with unusual speed.

Pharmacogeneticists sort individuals into metabolizer categories based on the combined effect of their variants: poor, intermediate, extensive (normal), and ultrarapid. A poor metabolizer may accumulate plasma concentrations several times higher than average on an identical dose; an ultrarapid metabolizer may clear the same substance so quickly that its expected effect barely materialises.

These differences trace back to specific inherited changes — a single substituted nucleotide, a deleted segment, or an extra gene copy inherited from one parent.

Relevance to substances & effects

Genotype shapes response across a wide range of substance classes. Opioid prodrugs such as codeine and tramadol depend on CYP2D6 to convert into their pharmacologically active forms; a poor metabolizer may feel little therapeutic effect, while an ultrarapid metabolizer can reach exposures that carry risk at ordinary doses. Many antidepressants — SSRIs, tricyclics, SNRIs — are substrates for the same enzymes, so genotype influences both efficacy and side-effect burden in that class as well.

Genotype is never the complete picture. Age, body composition, liver health, diet, and co-administered substances all modulate drug exposure alongside it. Enzyme-inhibiting substances can temporarily push an extensive metabolizer toward poor-metabolizer behaviour, producing an interaction that mimics a genotype the individual does not actually carry. For substances with steep dose-response curves or narrow margins, these overlapping variables — genotype among them — make individual response genuinely difficult to predict from dose alone.